TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16849753

Group type: EXPERIMENTAL
Intervention: Cannabis extract (CE) - 2.5 mg THC and 1 mg cannabidiol, orally, twice daily for 6 weeks
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC) - 2.5 mg, orally, twice daily for 6 weeks
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo (PL) - orally, twice daily for 6 weeks
Number of subjects: 243
Study: 15262604

Group type: EXPERIMENTAL
Intervention: 8 microg/kg intrathecal morphine sulfate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sterile normal saline placebo
Number of subjects: 100
Study: 10690662

Group type: EXPERIMENTAL
Intervention: Very-low-birthweight teeth
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Low-birthweight teeth
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal-birthweight controls
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mandibular and maxillary lateral incisors of very-low-birthweight children
Number of subjects: 111
Study: 9101427

Group type: EXPERIMENTAL
Intervention: Low SAT Diet (25% fat, 6% saturated fatty acids)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Step-One Diet (29% fat, 9% saturated fatty acids)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Average American Diet (34% fat, 15% saturated fatty acids)
Number of subjects: 25
Study: 8468114

Group type: EXPERIMENTAL
Intervention: Amikacin once daily (single injection)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Amikacin twice daily (two injections at 12-hour interval)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Amikacin (both groups)
Number of subjects: 39
Study: 3514832

Group type: EXPERIMENTAL
Intervention: Untreated own mother's milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled pasteurized breast milk
Number of subjects: 0
Study: 31608773

Group type: EXPERIMENTAL
Intervention: Multimodal behavioral intervention including yoga, memory compensation training, computerized cognitive training, support groups, and wellness education
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Group support
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Higher educational level, higher baseline depressive symptoms, higher baseline global cognitive functioning, and better baseline and concurrent functional abilities
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Changes in functional abilities
Number of subjects: 272
Study: 29911495

Group type: EXPERIMENTAL
Intervention: Prone Yo-Yo Intermittent Recovery Test Level 1 (Yo-Yo IR1)
Number of subjects: 17
Study: 27239315

Group type: EXPERIMENTAL
Intervention: Physical activity (active vs inactive) in males
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Waist circumference in females
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Baseline hypertension and family history of diabetes
Number of subjects: 334
Study: 24176067

Group type: EXPERIMENTAL
Intervention: Serum unbound free fatty acid (FFAu) levels
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: FFAu levels in the fourth quartile
Number of subjects: 1834
Study: 23801529

Group type: EXPERIMENTAL
Intervention: lisdexamfetamine (30, 50 or 70 mg/day)
Number of subjects: 336

Group type: COMPARATOR
Intervention: OROS-MPH (18, 36 or 54 mg/day)
Number of subjects: 336

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Number of subjects: 336
Study: 20420753

Group type: EXPERIMENTAL
Intervention: 13C-labelled phylloquinone from kale
Number of subjects: 7
Study: 17919605

Group type: EXPERIMENTAL
Intervention: Heated car seat
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unheated car seat
Number of subjects: 30
Study: 15945502

Group type: EXPERIMENTAL
Intervention: Inhaled beta2-agonists, beclomethasone, disodiumcromoglycate, and immunotherapy (for 14 patients in group a and 28 patients in group b)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inhaled beta2-agonists, beclomethasone, disodiumcromoglycate (without immunotherapy for 14 patients in group c)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Follow-up after five years for group (b)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study: 12861258

Group type: EXPERIMENTAL
Intervention: Work methodology for enuresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol based on anamnesis and urine analysis
Number of subjects: 0
Study: 9835000

Group type: EXPERIMENTAL
Intervention: Epicardial two‐dimensional echocardiography using a 7.5 MHz cm2 transducer
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calculated CSA from the most suitable diameter assuming vessel circularity
Number of subjects: 23
Study: 8983929

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no IFN)
Number of subjects: 0
Study: 2523664

Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Isradipine (0.5, 1.25, or 2.5 mg twice daily)
Number of subjects: 178
Study: 951465

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oxprenolol (320 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 3
Study: 31907840

Group type: EXPERIMENTAL
Intervention: Attention spanned both stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention focused on a single object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrowed categories to the basic level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prioritized object category in distractor's location
Number of subjects: 0
Study: 31849032

Group type: EXPERIMENTAL
Intervention: ALO‐02 (20‐160 mg oxycodone)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study: 29799344

Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg/hr or adjusted to clinical effect)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine (1.0 mg/kg/hr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine (0.85 mg/kg/hr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine (0.70 mg/kg/hr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine (0.55 mg/kg/hr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketamine (any dose)
Number of subjects: 10
Study: 27315439

Group type: EXPERIMENTAL
Intervention: Enhanced Sensory High Energy (ESHE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enhanced Sensory Low Energy (ESLE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low Sensory High Energy (LSHE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low Sensory Low Energy (LSLE)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High Energy (HE) drinks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enhanced Sensory (ES) drinks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enhanced Sensory High Energy (ESHE) drink
Number of subjects: 23
Study: 25087308

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music during surgery)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No music therapy (control group)
Number of subjects: 110
Study: 22051153

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg, once daily; n = 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 59
Study: 19461428

Group type: EXPERIMENTAL
Intervention: Moderate postpartum hemorrhage
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Severe postpartum hemorrhage
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Retained placenta
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Multiple pregnancy
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Macrosomia
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Need for perineal suture
Number of subjects: 11323

Group type: EXPERIMENTAL
Intervention: Induced labor
Number of subjects: 11323
Study: 17230618

Group type: EXPERIMENTAL
Intervention: subcutaneous rhGH (0.15 IU/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo (menstruum)
Number of subjects: 48
Study: 15039245

Group type: EXPERIMENTAL
Intervention: 2 x 300 mg bupropion (BUP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo capsules (lactose)
Number of subjects: 8
Study: 11755834

Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15% twice daily
Number of subjects: 556

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 556

Group type: COMPARATOR
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 556

Group type: COMPARATOR
Intervention: Unoprostone vs Timolol
Number of subjects: 556

Group type: COMPARATOR
Intervention: Unoprostone vs Betaxolol
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Unoprostone
Number of subjects: 556

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 556

Group type: COMPARATOR
Intervention: Betaxolol
Number of subjects: 556

Group type: COMPARATOR
Intervention: Unoprostone, Timolol, Betaxolol
Number of subjects: 556
Study: 10395270

Group type: COMPARATOR
Intervention: Gore-tex grafts (100 grafts)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Impra grafts (90 grafts)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Gore-tex grafts
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Impra grafts
Number of subjects: 168
Study: 7657769

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 2565585

Group type: EXPERIMENTAL
Intervention: Essential fatty acid (EFA) supplementation
Number of subjects: 0
Study: 1063593

Group type: EXPERIMENTAL
Intervention: Combined 6-mercaptopurine and methotrexate maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 0
Study: 31042340

Group type: EXPERIMENTAL
Intervention: Experimental teams with resuscitation-automating devices and goal-directed protocols
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control teams with standard protocols and equipment
Number of subjects: 20
Study: 28387927

Group type: EXPERIMENTAL
Intervention: ITALUNG biomarker panel (IBP)
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Multimodal screening (IBP + LDCT)
Number of subjects: 1356

Group type: COMPARATOR
Intervention: LDCT (Low Dose Computed Tomography)
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Single test (IBP)
Number of subjects: 1356
Study: 25869689

Group type: EXPERIMENTAL
Intervention: Glucomannan (GNN) at a dose of 3 g/day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) at a dose of 3 g/day for 3 months
Number of subjects: 0
Study: 23713521

Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015% (Saflutan®) once daily
Number of subjects: 100
Study: 21343386

Group type: EXPERIMENTAL
Intervention: Kneehab (novel garment‐integrated neuromuscular electrical stimulation)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polystim (traditional neuromuscular electrical stimulation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (standard rehabilitation program)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Kneehab
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polystim
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 19730234

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 197

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 197
Study: 17160649

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with bupivacaine and fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) using morphine
Number of subjects: 50
Study: 14985690

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched milk
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched yoghurt
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched bread
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched cereal
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched milk and bread
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched bread and milk
Number of subjects: 58
Study: 11805564

Group type: EXPERIMENTAL
Intervention: Closed technique (electrodes placed through the sacral foramen)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Open technique (cuff electrodes placed after sacral laminectomy)
Number of subjects: 6
Study: 9185038

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1946567

Group type: EXPERIMENTAL
Intervention: Sensory cues of cigarette smoking (with minimal nicotine, 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoke containing 0.5 mg of nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 0
Study: 6756019

Group type: EXPERIMENTAL
Intervention: 4 mg morphine administered epidurally
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2 mg morphine administered epidurally
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30755343

Group type: EXPERIMENTAL
Intervention: Crevicular incision with vertical release
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine vestibular incision
Number of subjects: 60
Study: 29281868

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (10 sessions of group therapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 25336746

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2765

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2765

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2765
Study: 24893332

Group type: EXPERIMENTAL
Intervention: koumiss + exercise (KE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: koumiss (K)
Number of subjects: 18

Group type: COMPARATOR
Intervention: exercise alone (E)
Number of subjects: 18
Study: 22691647

Group type: EXPERIMENTAL
Intervention: Hemostatic matrix
Number of subjects: 349

Group type: COMPARATOR
Intervention: Conventional hemostatic methods (controls)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 349

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 349
Study: 20207458

Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate (1.35% taurolidine and 4% citrate)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Heparin (5,000 U/mL)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 110
Study: 18341596

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily, given as 50 mg twice daily)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Acarbose (up to 300 mg daily, given as three equally divided doses)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 661

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 661
Study: 15974220

Group type: EXPERIMENTAL
Intervention: Battery-powered toothbrush (Oral-B Kids)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 30
Study: 12809822

Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard mail survey
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telephone survey
Number of subjects: 100
Study: 10492405

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml (300 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bupivacaine 5 mg/ml (200 mg)
Number of subjects: 104
Study: 8922653

Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ibandronate 5.0 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ibandronate 0.25 mg
Number of subjects: 180
Study: 1352717

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 14
Study: 3993558

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study: 31353302

Group type: EXPERIMENTAL
Intervention: Continuous Interscalene Blockade (ISB)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Single-injection ISB
Number of subjects: 129

Group type: COMPARATOR
Intervention: Local Infiltration Analgesia
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Continuous ISB
Number of subjects: 129
Study: 29405507

Group type: COMPARATOR
Intervention: Sham pill described as 'a well‐known tablet available without prescription'
Number of subjects: 203
Study: 26758502

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (5 ml/d, 1.2 g/d n-3 long-chain PUFA)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sunflower oil (SO) supplementation
Number of subjects: 115
Study: 25452376

Group type: EXPERIMENTAL
Intervention: Retention of syndesmotic screw
Number of subjects: 51

Group type: COMPARATOR
Intervention: Removal of syndesmotic screw
Number of subjects: 51
Study: 22565140

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 20597040

Group type: EXPERIMENTAL
Intervention: Metered pump spray application of nasal steroid
Number of subjects: 11

Group type: COMPARATOR
Intervention: Inhalation using the Pari sinus device
Number of subjects: 11
Study: 17905165

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - either rosiglitazone or pioglitazone
Number of subjects: 20191

Group type: COMPARATOR
Intervention: Control (comparators)
Number of subjects: 20191
Study: 16230896

Group type: EXPERIMENTAL
Intervention: Phase-preserving amplification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-phase-preserving amplification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both amplification types
Number of subjects: 0
Study: 12171453

Group type: EXPERIMENTAL
Intervention: Nutrient‐dense protein‐energy liquid supplement and encouragement to improve intake from other foods
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 10546234

Group type: EXPERIMENTAL
Intervention: Osteoporosis patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Osteoporosis patients with at least one vertebral fracture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (11 male patients with monoclonal gammopathy of undetermined significance)
Number of subjects: 44
Study: 7538403

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 6 U/day subcutaneously
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2073488

Group type: EXPERIMENTAL
Intervention: Subarachnoid clonidine (150 micrograms)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral diazepam (10 mg)
Number of subjects: 36
Study: 6778335

Group type: EXPERIMENTAL
Intervention: Surgical treatment including myringotomy and aeration tube insertion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonadenoidectomy
Number of subjects: 0
Study: 31765383

Group type: EXPERIMENTAL
Intervention: Household sanitation facility use
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: School sanitation coverage > 3 toilets per 100 pupils
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: Village sanitation coverage > 81%
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: General contextual effects from village and school domains
Number of subjects: 4104

Group type: COMPARATOR
Intervention: School sanitation
Number of subjects: 4104

Group type: COMPARATOR
Intervention: Village sanitation
Number of subjects: 4104
Study: 28802789

Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 26509673

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 14
Study: 22858209

Group type: EXPERIMENTAL
Intervention: Factor analysis and cluster analysis conducted on all subjects using Young Mania Rating Scale and Montgomery‐Åsberg Depression Scale.
Number of subjects: 2179

Group type: EXPERIMENTAL
Intervention: Analysis conducted separately for DSM-IV mixed episodes (n=644) and non-mixed episodes (n=1535).
Number of subjects: 2179
Study: 21211004

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMPD1 34C > T variant
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LPS (2 ng/kg E. Coli LPS)
Number of subjects: 30
Study: 19122556

Group type: EXPERIMENTAL
Intervention: remifentanil 2 microg kg(‐1) (group R)
Number of subjects: 105

Group type: COMPARATOR
Intervention: sufentanil 0.2 microg kg(‐1) (group S)
Number of subjects: 105
Study: 17223209

Group type: EXPERIMENTAL
Intervention: Plasma apelin levels in IDC patients (median 26.5 pg/ml, range <3.40-97.6 pg/ml)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: NT‐proBNP, IL‐6, TNF‐alpha, norepinephrine levels
Number of subjects: 65
Study: 15587238

Group type: EXPERIMENTAL
Intervention: Smith Irrational Beliefs Inventory
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Factor analyses (alpha factoring, direct oblimin rotation)
Number of subjects: 1851
Study: 11553198

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 517

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 517
Study: 9671087

Group type: EXPERIMENTAL
Intervention: Active compression‐decompression (ACD) CPR
Number of subjects: 576

Group type: COMPARATOR
Intervention: Standard CPR (STD-CPR)
Number of subjects: 576